The evolving role of lenalidomide in the treatment of hematologic malignancies

被引：47

作者：

Kastritis, Efstathios ^{[1
]}

Dimopoulos, Meletios A. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Clin Therapeut, Alexandra Hosp, GR-11527 Athens, Greece

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 04期

关键词：

D O I：

10.1517/14656566.8.4.497

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, which has pleotropic activity, including antiangiogenic and antineoplastic properties. This agent is the product of advances in the understanding of the biology of neoplastic cells, their interaction with the microenvironment and of the underlying molecular pathways. Lenalidomide has shown significant activity in refractory/resistant multiple myeloma, and further studies have shown its activity in other hematologic malignancies with some very encouraging results, especially in subsets of patients with myelodysplastic syndromes. This article reviews the data on lenalidomide use in patients with multiple myeloma, as well as in myelodysplastic syndromes, chronic lymphocytic leukemia and myelofibrosis with myeloid metaplasia.

引用

页码：497 / 509

页数：13

共 77 条

[41] A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia [J].

Mesa, RA ;

Steensma, DP ;

Pardanani, A ;

Li, CY ;

Elliott, M ;

Kaufmann, SH ;

Wiseman, G ;

Gray, LA ;

Schroeder, GE ;

Reeder, T ;

Zeldis, JB ;

Tefferi, A .

BLOOD, 2003, 101 (07) :2534-2541

[42]

Mitsiades Constantine S, 2004, Curr Opin Investig Drugs, V5, P635

[43] Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications [J].

Mitsiades, N ;

Mitsiades, CS ;

Poulaki, V ;

Chauhan, D ;

Richardson, PG ;

Hideshima, T ;

Munshi, NC ;

Treon, SP ;

Anderson, KC .

BLOOD, 2002, 99 (12) :4525-4530

[44] How I treat refractory CLL [J].

Montserrat, E ;

Moreno, C ;

Esteve, J ;

Urbano-Ispizua, A ;

Giné, E ;

Bosch, F .

BLOOD, 2006, 107 (04) :1276-1283

[45] THALIDOMIDE EXERTS ITS INHIBITORY-ACTION ON TUMOR-NECROSIS-FACTOR-ALPHA BY ENHANCING MESSENGER-RNA DEGRADATION [J].

MOREIRA, AL ;

SAMPAIO, EP ;

ZMUIDZINAS, A ;

FRINDT, P ;

SMITH, KA ;

KAPLAN, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (06) :1675-1680

[46]

MUSIAL L, 2006, J CLIN ONCOL, V24, P18512

[47] Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives [J].

Musto, P .

LEUKEMIA RESEARCH, 2004, 28 (04) :325-332

[48] THALIDOMIDE AND THE IMMUNE-SYSTEM .3. SIMULTANEOUS UP-REGULATION AND DOWN-REGULATION OF DIFFERENT INTEGRIN RECEPTORS ON HUMAN WHITE BLOOD-CELLS [J].

NOGUEIRA, AC ;

NEUBERT, R ;

HELGE, H ;

NEUBERT, D .

LIFE SCIENCES, 1994, 55 (02) :77-92

[49] The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) [J].

Palladini, G ;

Perfetti, V ;

Perlini, S ;

Obici, L ;

Lavatelli, F ;

Caccialanza, R ;

Invernizzi, R ;

Comotti, B ;

Merlini, G .

BLOOD, 2005, 105 (07) :2949-2951

[50]

Palumbo A, 2006, J CLIN ONCOL, V24, p426S

← 1 2 3 4 5 6 7 8 →